Healthcare / Medical DevicesTSXV
$0.27
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.1M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
N/A
•EV/EBITDA
N/A
•ROE
113.8%
↑Gross Margin
83.6%
↑Debt/Equity
-1.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
+322.1%
FCF CAGR
—
FCF margin
-277.2%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.1M · net income $-20.5M · FCF $-25.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $9.1M | $9.1M | $2.2M |
| Net Income | $-20.5M | $-20.5M | $-43.6M |
| EBITDA | $-8.0M | $-8.0M | $-34.6M |
| EPS | -0.36 | -0.36 | -0.99 |
| Gross Margin | 83.6% | 83.6% | 2.5% |
| Operating Margin | -162.8% | -162.8% | -1213.9% |
| Net Margin | -224.9% | -224.9% | -2018.3% |
| Balance Sheet | |||
| Debt/Equity | -1.10 | -1.10 | -0.55 |
| Current Ratio | 0.60 | 0.60 | — |
| Cash Flow | |||
| Free Cash Flow | $-25.3M | $-25.3M | $-21.0M |
| Returns | |||
| ROE | 113.8% | 113.8% | 50.8% |
| Growth & Yield | |||
| Revenue Growth | 322.1% | 322.1% | — |
| EPS Growth | 63.5% | 63.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.99 → -0.36
Residual
-32.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.